[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"takotsubo-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:takotsubo-cardiomyopathy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,66,95,121,146,168,191,219,240,263,298,322],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100514327","psychosocial-support-for-patients-with-takotsubo-syndrome-100514327",false,"NCT05977049","Psychosocial Support for Patients With Takotsubo Syndrome","Inclusion Criteria:\n\n\\- All patients with documented diagnosis of Takotsubo Syndrome greater than 18 years old.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of Takotsubo Syndrome already undergoing Psychotherapy or those who choose not to participate.\n* Vulnerable populations such as prisoners, non-English speaking subjects, pregnant women, and subjects unable to provide written informed consent will not be included in this research.","ALL","18 Years",{"count":18,"type":19},24,"ESTIMATED","INTERVENTIONAL",[22],"NA","The study hypothesis is that participants enrolled in a virtual Takotsubo support group will have significantly less anxiety at one year.",[25],"Takotsubo Cardiomyopathy",[27,28,29],"Takotsubo","Cardiomyopathy","Takotsubo Syndrome","RECRUITING","2026-06-11",{"date":33,"type":34},"2026-06-15","ACTUAL",{"date":36,"type":34},"2024-04-17",{"date":38,"type":19},"2027-12-31",{"name":40,"class":41},"Weill Medical College of Cornell University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100401884","is-there-a-genetic-predisposition-for-acute-stress-induced-takotsubo-cardiomyopathy-100401884","NCT04513054","Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy","Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy: The GENETIC Study","GENETIC","Inclusion Criteria:\n\n* All patients who have been diagnosed with Takotsubo cardiomyopathy in Scotland between 2010 to date.\n* Familial cases elsewhere in the world who would be willing to participate.\n\nExclusion Criteria:\n\n* Unwillingness to participate",{"count":52,"type":19},700,[22],"Acute stress-induced (takotsubo) cardiomyopathy or broken heart syndrome presents like a heart attack, classically is triggered by intense emotional or physical stress and can have serious health consequences. In the current study the investigators wish to establish whether there is a genetic predisposition making certain people more susceptible to this condition. This could also have implications for their families.",[25],"2026-04-29",{"date":58,"type":34},"2026-04-30",{"date":60,"type":34},"2019-03-12",{"date":62,"type":19},"2028-12-31",{"name":64,"class":41},"University of Aberdeen",2,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":20,"phases":76,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":18},"100512001","phase-2-cyclosporine-in-takotsubo-syndrome-100512001","NCT05946772","Cyclosporine In Takotsubo Syndrome","Cyclosporine In Takotsubo Syndrome (CIT) Trial","CIT","Key inclusion criteria:\n\n* Patients aged over 18\n* Enrollment and first IMP administration within 24 hours after cardiac catheterization\n* Regional Wall Motion Abnormality (WMA) consistent with TTS in angiography or echocardiography\n* InterTAK prognostic score- or a GEIST Score ≥ 9 -\n* Written informed consent\n\nKey exclusion Criteria:\n\n* Acute coronary syndrome (ACS) with significant coronary stenosis potentially associated with wall motion abnormalities (WMA) or percutaneous coronary intervention (PCI)\n* Infection (defined as concomitant infection with a positive blood culture at the time of study inclusion)\n* History of hypersensitivity to cyclosporine\n* History of hypersensitivity to egg, peanut or soybean proteins\n* History of chronic renal insufficiency (either creatinin clearance \\\u003C30 ml\u002Fmin\u002F1.73m² or current medical care for severe renal insufficiency)\n* History of liver insufficiency\n* Uncontrolled hypertension at the time of screening for study inclusion (systolic blood pressure \\>180mmHg and\u002For diastolic blood pressure \\>110mmHg)\n* Current medication with any compound containing Hypericum perforatum (St. John's worth) or Stiripentol or Aliskiren or Bosentan or Rosuvastatine (Rosuvastatine \\>5mg within 24h intake\\\u003C48h before IMP administration)\n* Female patients currently pregnant or women of childbearing age without negative pregnancy test or without effective contraception\n* Any disorder associated with immunological dysfunction ≤6 months prior to presentation (autoimmune disease, known positive serology for HIV or hepatitis)\n* Immunosuppressive, chemotherapeutical, or antibody treatment\n* Participation in other clinical trials except for non interventional trials",{"count":75,"type":19},204,[77],"PHASE2","The goal of this clinical trial is to investigate the impact of repetitive acute Cyclosporine A (CsA) bolus therapy in patients suffering from TTS with an elevated risk of impaired outcome. The main question it aims to answer is whether CsA reduces myocardial injury (primary outcome). Participants will receive CsA or placebo at baseline and every 12h in the first 24h after study inclusion. Researchers will compare CsA and the placebo group to see if a) myocardial injury is reduced, and b) ejection fraction is improved compared to baseline, as well as several other secondary endpoints over a one year follow-up.",[25],[81,82,83,84,85],"Takotsubo syndrome","Troponin","Cyclosporine","Inflammation","Acute heart failure","2026-04-27",{"date":88,"type":34},"2026-05-01",{"date":90,"type":34},"2025-02-01",{"date":92,"type":19},"2028-02",{"name":94,"class":41},"University Hospital Heidelberg",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":20,"phases":105,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":42},"100630749","manganese-enhanced-magnetic-resonance-imaging-in-takotsubo-cardiomyopathy-100630749","NCT07491718","Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy","TAKO MEMRI","Inclusion Criteria:\n\n* Males and females \\>18 years of age\n* Clinical presentation of takotsubo cardiomyopathy\n* Have capacity to give formal consent\n\nExclusion Criteria:\n\n* Unable to tolerate or contraindication to magnetic resonance imaging\n* Renal failure (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m2) - this would be assessed by performing a blood test\n* Prior history of cardiomyopathy\n* Current pregnancy\n* Weight greater than 250kg\n* Severe asthma for study 1 (given Bisoprolol is contraindicated in this condition)\n* Type 1 diabetes mellitus for study 2 (given Dapaglifozin is contraindicated in this population)\n* Significant hypotension (given the medications prescribed as part of the study can also cause hypotension as a side effect)\n* Significant bradycardia for study 1 (given Bisoprolol can exacerbate any pre-existing significant bradycardia)\n* Prescribed Digoxin (this medication interacts with the Manganese)\n* Unable to give formal consent",true,{"count":104,"type":19},100,[22],"The goal of this research study is to further understand the physiological mechanisms involved in a heart condition called takotsubo cardiomyopathy, also known as broken heart syndrome. Furthermore, the investigators will be assessing the effects different cardiac medications have on these physiological mechanisms.\n\nThis will be achieved by performing cardiac MRI scans using a special dye called manganese. Manganese uptake in the heart is altered in patients with takotsubo cardiomyopathy. The investigators will study the effects that different cardiac medications have on manganese uptake.",[25],[27,109,110,111],"Broken heart syndrome","Stress cardiomyopathy","Manganese","2026-03-18",{"date":114,"type":34},"2026-03-24",{"date":116,"type":34},"2025-08-08",{"date":118,"type":19},"2028-08-09",{"name":120,"class":41},"University of Edinburgh",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":128,"enrollmentInfo":129,"targetDuration":131,"studyType":132,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":42},"100336663","registry-of-patients-with-takotsubo-syndrome-100336663","NCT03663348","Registry of Patients With Takotsubo Syndrome","NYU Takotsubo (Broken Heart Syndrome) Registry","Inclusion Criteria:\n\n* Physician diagnosis of takotsubo syndrome\n* Age\\>18 years\n\nExclusion Criteria:\n\n\\- Lack of capacity to provide informed consent","110 Years",{"count":130,"type":19},500,"10 Years","OBSERVATIONAL","Takotsubo syndrome is a condition which mimics acute myocardial infarction, and is diagnosed in 1.5% to 2.2% of patients referred to hospital with suspected acute coronary syndrome. It is also known as broken heart syndrome, takotsubo cardiomyopathy, stress cardiomyopathy and apical ballooning cardiomyopathy, among other names. The pathogenesis of this disorder is not well understood. Possible mechanisms include catecholamine excess, coronary artery spasm, microvascular dysfunction, among others. This is a multicenter, nation-wide, observational study of patients who were previously diagnosed with takotsubo syndrome. The investigators aim to use this registry to help plan and carry out further studies and to improve understanding of the pathophysiologic mechanisms of this syndrome. In addition participants will be followed for events, and to monitor quality of life and stress.",[25,135,136],"Broken Heart Syndrome","Tako-tsubo Cardiomyopathy","2025-12-23",{"date":139,"type":34},"2025-12-30",{"date":141,"type":34},"2009-09-11",{"date":143,"type":19},"2029-08-01",{"name":145,"class":41},"NYU Langone Health",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":153,"targetDuration":155,"studyType":132,"phases":4,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":42},"100355637","the-cedars-sinai-smidt-heart-institute-takotsubo-registry--proteomic-study-100355637","NCT03910569","The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study","Smidt Heart Institute Takotsubo Registry","Inclusion Criteria:\n\n* Have received a diagnosis of Takotsubo from their physician and consent to enroll\n* Submit full medical records needed for Takotsubo adjudication\n\nExclusion Criteria:\n\n* Younger than 18 years\n* Unable to provide informed consent\n* Unable to provide the necessary documentation needed for screening purposes",{"count":154,"type":19},1000,"30 Years","The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion\u002Fexclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.",[25],[27],"2025-08-15",{"date":161,"type":34},"2025-08-20",{"date":163,"type":34},"2019-02-01",{"date":165,"type":19},"2029-02",{"name":167,"class":41},"Cedars-Sinai Medical Center",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":42},"100537397","prognotic-role-of-cmr-in-takotsubo-syndrome-100537397","NCT06277297","Prognotic Role of CMR in Takotsubo Syndrome","Exploring the eVolution in prognOstic capabiLity of mUlti-sequence Cardiac magneTIc resOnance in patieNts Affected by Takotsubo Cardiomyopathy","EVOLUTION","Inclusion Criteria:\n\n* Takotsubo syndrome diagnosis (according to Position Statement of the European Society of Cardiology Heart Failure Association)\n* Adult patients ( \\> 18y old)\n* Availability at baseline of clinical variables, standard transthoracic echocardiography, and cardiovascular magnetic resonance acquisition\n\nExclusion Criteria:\n\n* \\\u003C18 y old\n* Lack of transthoracic echocardiography and cardiovascular magnetic resonance examinations\n* Preexisting cardiomyopathies\n* Previous myocardial infarction\n* Suspected or known prior irreversible myocardial damage\n* Valvular heart disease",{"count":177,"type":19},350,"The primary objective of this observational registry is to develop a comprehensive clinical and imaging score (incorporating echocardiography and cardiac magnetic resonance data) that enhances risk stratification for patients with Takotsubo syndrome.\n\nThe secondary objectives of this registry are as follows:\n\nInvestigate the diagnostic value of cardiac magnetic resonance parameters in predicting in-hospital and long-term outcomes in patients with Takotsubo syndrome.\n\nCompare the proposed risk stratification score for patients with Takotsubo syndrome with previously existing scores.\n\nInvestigate the contribution of machine learning models in predicting in-hospital and long-term outcomes compared to standard clinical scores.\n\nThe design and rationale of this registry are available at 10.1097\u002FRTI.0000000000000709",[25,180,181],"Machine Learning","Magnetic Resonance Imaging","2025-06-04",{"date":184,"type":34},"2025-06-08",{"date":186,"type":34},"2022-11-09",{"date":188,"type":19},"2032-11",{"name":190,"class":41},"University of Cagliari",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":42},"100561989","cardiac-assessment-and-takotsubo-stunning-among-copd-exacerbations-in-hospital-100561989","NCT06597331","Cardiac Assessment and Takotsubo-stunning Among COPD-exacerbations In-Hospital","Prospective Observational Study of Myocardial Stunning in Patients Hospitalized for Exacerbation of Chronic Obstructive Pulmonary Disease","CATCH","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old) admitted to hospital ward for AE-COPD\n* Inclusion within 72 hours of admission,\n* Written informed consent\n\nExclusion Criteria:\n\n* Prior acute myocardial infarction or known pre-existing persistent regional wall motion abnormality or left ventricular dysfunction (left ventricular ejection fraction \\[LVEF\\] \\\u003C50%)\n* Expected inability to comply with the protocol (e.g. dementia)",{"count":200,"type":19},200,"The goal of this prospective observational study is to investigate to what extent acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) triggers Takotsubo-stunning, and how this affects the outcome for these patients.\n\nThe main questions it aims to answer are:\n\n1. What is cumulative incidence of Takotsubo-stunning in patients hospitalized for AE-COPD at Sahlgrenska University Hospital\u002FS (Gothenburg, Sweden)?\n2. Among patients hospitalized for AE-COPD at Sahlgrenska University Hospital\u002FS, what is the risk of in-hospital clinical manifestations of acute heart failure in patients with Takotsubo-stunning compared to those without?",[203,25,204],"Chronic Obstructive Pulmonary Disease","Acute Heart Failure",[81,206,207,208,209],"COPD","Echocardiography","Screening","Trigger","2025-05-09",{"date":212,"type":34},"2025-05-14",{"date":214,"type":34},"2024-09-23",{"date":216,"type":19},"2027-09-01",{"name":218,"class":41},"Sahlgrenska University Hospital",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":227,"targetDuration":229,"studyType":132,"phases":4,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":42},"100308765","establishing-the-incidence-of-tako-tsubo-cardiomyopathy-in-scotland-100308765","NCT03299569","Establishing the Incidence of Tako-tsubo Cardiomyopathy in Scotland","Establishing the Incidence of Tako-tsubo Cardiomyopathy in Scotland - the STARR Study","STARR","Inclusion Criteria:\n\n* All patients diagnosed with Takotsubo cardiomyopathy\n\nExclusion Criteria:\n\n* NA",{"count":228,"type":19},800,"13 Years","Acute stress-induced (Takotsubo cardiomyopathy) presents like a heart attack and is triggered by intense emotional or physical stress. Although coronary arteries are unobstructed, it has been suggested that the risk of death is similar to a myocardial infarction. The purpose of the STARR study is to identify all cases of Takotsubo in Scotland since 2010 and assess its epidemiology and outcomes.",[25,232],"Myocardial Infarction","2025-03-19",{"date":235,"type":34},"2025-03-24",{"date":237,"type":34},"2016-07-29",{"date":62,"type":19},{"name":64,"class":41},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":20,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":42},"100541668","effectiveness-of-a-resilience-based-rehabilitation-program-for-patients-with-coronary-heart-disease-100541668","NCT06332859","Effectiveness of a Resilience-Based Rehabilitation Program for Patients with Coronary Heart Disease","Effectiveness of a Resilience-based Rehabilitation Program in Patients with TakoTsubo Cardiomyopathy and After Acute Coronary Syndrome","Inclusion Criteria:\n\n* patients experienced TakoTsubo cardiomyopathy (I42.88, I42.9) or patients after an acute coronary event (I21.9) (max. 6 month post event)\n* older than 18 years\n* signed consent form\n\nExclusion Criteria:\n\n* Acute intercurrent illness (longer than 3 days)\n* No sufficient knowledge of German to enable participation in the resilience training (assessment by recruiting person)",{"count":248,"type":19},130,[22],"To handle daily life challenges, one needs to be psychologically resilient. It plays a crucial role in disease development, prognosis, as well as social, occupational, and community participation. Cardiovascular diseases cause physical and psychological stress, which can be linked to individual resilience and the development of such diseases. Stress can trigger TakoTsubo cardiomyopathy and acute coronary events. Individuals who have experienced TakoTsubo cardiomyopathy or an acute coronary event often feel stressed due to emotional or physical triggers. These triggers may include job loss or illness. In medical rehabilitation, therapists consider the individual circumstances of their patients when planning therapy. It may be important to add a special focus on psychological care, including building resilience, which could greatly benefit these individuals. Therefore, the study aims to investigate whether resilience training, as part of an inpatient multidisciplinary rehabilitation program, affects the individual resilience of rehabilitants with TakoTsubo cardiomyopathy or those who have experienced an acute coronary event.",[25,252,253],"Acute Coronary Syndrome","Psychological Resilience","2025-03-06",{"date":256,"type":34},"2025-03-10",{"date":258,"type":34},"2024-04-15",{"date":260,"type":19},"2026-10-14",{"name":262,"class":41},"Pensionsversicherungsanstalt",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":20,"phases":272,"briefSummary":274,"conditions":275,"keywords":278,"overallStatus":288,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":42},"100555206","phase-4-beta-blockers-in-takotsubo-syndrome-study-100555206","NCT06509074","Beta-Blockers in Takotsubo Syndrome Study","Beta-Blockers in Takotsubo Syndrome Study: A Randomized Clinical Trial (β-Tako)","β-Tako","Inclusion Criteria:\n\n* Written informed consent.\n* Diagnosis of TTS with exclusion of significant coronary artery disease (CAD) by invasive coronary angiography\n\nExclusion Criteria:\n\n* Patients diagnosed of TTS \\> 48 hours before.\n* Persistent ccardiogenic shock or severe hemodynamic instability\n* Persistent severe (\\>30 mmHg) intraventricular gradient\n* Previous diagnosis of severe valvular or ventricular disease or prior myocardial infarction secondary to atherosclerotic CAD\n* Patients already receiving treatment with betablockers (\\*)\n* Absolute contraindication\u002Findication for beta-blockers (\\*\\*)\n* Poor echocardiographic window\n* Pregnant or breastfeeding women.\n* Participation in another clinical trial.\n\n(\\*) Betablockers at a therapeutic dose at the time of symptom´s onset. (\\*\\*) Close ECG monitoring required in patients with hypotension, bradycardia or cQT interval prolongation",{"count":200,"type":19},[273],"PHASE4","The Beta-blockers in Takotsubo syndrome (TTS) (β-Tako) trial, is an academic, pragmatic, prospective, multicenter randomized clinical trial, aiming to assess the efficacy of beta-blockers (BB) in TTS patients. Two-hundred patients with TTS will be randomized (1:1) to BB (n=100) or no BB (n=100). BB with alpha or nitric oxide release activity will be used in the treatment arm. The primary endpoint will be the comparison of the wall motion score index by echocardiography at 7 days. A composite clinical endpoint (death, stroke, admission for recurrent TTS, ACS, heart failure or atrial fibrillation) at 1 year, will be assessed by an independent clinical events committee. Several sub-studies will be performed. The β-Tako trial will inform treatment decisions in this uniquely challenging clinical entity.",[25,276,207,277],"Beta-blockers","Left Ventricular Function",[25,279,280,281,282,283,284,285,286,287],"beta-blockers","echocardiography","left ventricular function","acute myocardial infarction","acute coronary syndrome","coronary angiography","Normal coronary arteries","Heart failure","stress","NOT_YET_RECRUITING","2024-08-21",{"date":291,"type":34},"2024-08-26",{"date":293,"type":19},"2024-08",{"date":295,"type":19},"2026-12",{"name":297,"class":41},"Spanish Society of Cardiology",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":102,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":42},"100554975","characterization-of-acute-myocardial-damage-with-spectral-computed-tomography-cadami-spectral-100554975","NCT06506071","Characterization of Acute Myocardial Damage With Spectral Computed Tomography. (CADAMI-SPECTRAL)","Characterization of Acute Myocardial Damage With Spectral Computed Tomography. CADAMI-SPECTRAL.","CADAMI","Inclusion Criteria:\n\n* Age ≥ 18 year.\n* Hospital admission due to chest pain and acute myocardial injury.\n* Clinical indication for cardiac MRI (CMR) due to suspected acute myocardial infarction with coronary angiography showing no significant lesions (\\\u003C50%) (MINOCA), acute myocarditis, or stress-induced cardiomyopathy.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Contraindications to undergo cardiac MRI and CT with administration of gadolinium and\u002For iodine-based contrast, respectively.\n* Pre-existing cardiomyopathy.\n* Pre-existing chronic ischemic heart disease.\n* Invasive coronary angiography showing coronary lesions ≥50%.",{"count":307,"type":19},300,"Clinical management of patients with chest pain and elevation of biomarkers of myocardial injury require an accurate diagnosis. Until now, cardiac magnetic resonance imaging (cMRI) is the gold standard for the diagnosis among myocarditis, stress cardiomyopathy, or inapparent ischemic damage. The development of spectral CT has opened up the possibility of characterizing the coronary anatomy and the myocardium in a single procedure. Our aim is to assess the diagnostic ability of differential patterns in first- pass perfusion and delayed iodine enhancement obtained by spectral CT in patients with acute myocardial injury. This study is designed as a prospective multicenter observational study with diagnostic intervention in 150 patients admitted with clinical indication of a cMRI due to suspicion of myocardial infarction with normal coronary arteries (MINOCA), myocarditis or stress cardiomyopathy who will undergo a CT study with double detector technology in two reference centers. A control group (n=150) with an indication for cardiac CT for another cause without coronary or structural heart disease will be included. The iodine maps obtained by spectral CT will be compared with the findings obtained with cMRI, both with conventional techniques and with artificial intelligence algorithms (deep learning). A year follow-up of the cohort will be carried out to assess whether the findings derived from the CT in this group of patients provide prognostic information",[310,25,311,312],"Myocarditis; Acute or Subacute","Infarction, Myocardial","Myocardial Injury","2024-07-19",{"date":315,"type":34},"2024-07-23",{"date":317,"type":34},"2022-09-01",{"date":319,"type":19},"2025-09-01",{"name":321,"class":41},"Salamanca University Hospital",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":20,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":42},"100500188","characterization-of-primary-and-secondary-stress-related-takotsubo-100500188","NCT05793008","Characterization of priMary And sEcondary STress Related takOtsubo","Characterization of priMary And sEcondary STress Related takOtsubo: the MAESTRO Pilot Study","MAESTRO","Inclusion Criteria:\n\nFor patients with TTS:\n\n* Informed consent signed by the patient or parent\u002Fguardian\u002Flegal representative.\n* TTS diagnosed based on modified Mayo Clinic Diagnostic Criteria as: (i) transient wall motion abnormality in the left ventricle beyond a single epicardial coronary artery distribution; (ii) absence of obstructive coronary artery disease or angiographic evidence of acute plaque rupture, which can explain the wall motion abnormality; (iii) new electrocardiographic abnormalities or elevation in cardiac troponin values; (iv) absence of pheochromocytoma or myocarditis. N.B. - All TTS diagnosis made according to Mayo Clinic Diagnostic Criteria will be a posterior compared to fulfil the new InterTAK Diagnostic Criteria (19). Myocarditis will be suspected based on clinical presentation (e.g. previous flu-like symptoms, increased inflammatory biomarkers) and confirmed by cardiac magnetic resonance.N.B. - Of note, primary TTS mainly concerns post-menopausal women with symptoms resulting from myocardial damage, emotional trigger, and evidence of normal coronary arteries at coronary angiography, whilst secondary TTS equally affects men and women, with physical triggers and in the presence of possible coronary artery disease at coronary angiography.\n\nFor patients with sepsis:\n\n* Informed consent signed by the patient or parent\u002Fguardian\u002Flegal representative.\n* Diagnosis of sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, which can be represented by an increase in the Sequential \\[Sepsis-related\\] Organ Failure Assessment (SOFA) score of 2 points or more.\n* Septic a shock, defined as vasopressor requirement to maintain a mean arterial pressure of 65 mmHg or greater and serum lactate level greater than 2 mmol\u002FL (\\>18 mg\u002FdL) in the absence of hypovolemia.\n* Sepsis-induced cardiomyopathy, defined as left ventricular systolic dysfunction (LVSD) and\u002For LV diastolic dysfunction (LVDD) following sepsis in patients without known structural or functional cardiac disease.\n\nExclusion Criteria:\n\n* Alternate diagnosis for the clinical presentation.\n* Contraindication to PET for patients with TTS (pregnancy, breast-feeding or patients considering becoming pregnant during the study period);\n* Patients with comorbidities having an expected survival \\\u003C1-year.",{"count":331,"type":19},60,[22],"Takotsubo syndrome (TTS) is an acute and reversible form of myocardial injury often preceded by a physical or emotional trigger. Although TTS was generally considered a benign disease for its reversible nature, it is now clear that hemodynamic and electrical instability during the acute phase exposes patients to frequent serious adverse in-hospital complications. However, the pathophysiology of TTS is far from being completely understood. Consistent evidence demonstrated that the environmental events experienced by most of these patients and perceived as stressful (both physical or emotional) induce a brain activation and a stress-related response, with increasing bioavailability of local and circulating stress mediators, such as catecholamine and cortisol, which showed to play a major role in the etiology of to the \"neurogenic stunning myocardium\" responsible for this clinical condition.\n\nPrimary and secondary TTS showed an important clinical heterogeneity identifying two different subtypes of patients with different outcomes and risk profiles. the invastigators hypothesize that a different activation of the brain structures involved in acute stress response, as well as a different exposure to chronic stress, may subtend the different clinical and risk profiles observed in primary vs. secondary TTS patients. Moreover, the invastigators hypothesize that distinct signatures of circulating biomarkers may be associated with these two categories of TTS patients. Therefore, identifying these specific signatures may help in the diagnosis of these patients and pave the way for the identification of specific pathophysiologic pathways and the development of future therapies.",[25,335],"Sepsis-induced Cardiomyopathy",[29,337,338,339,340,341],"Fisical trigger","Emotional trigger","Biomarker","Precision Medicine","Neuroimaging approach","2024-02-23",{"date":344,"type":34},"2024-02-26",{"date":346,"type":34},"2023-03-30",{"date":348,"type":19},"2026-09-02",{"name":350,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]